Literature DB >> 18948152

Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription.

Jin Kyung Shon1, Bo Hwa Shon, In Young Park, Su Ui Lee, Liu Fa, Keun Young Chang, Je Hoon Shin, Young Ik Lee.   

Abstract

Hepatitis B virus (HBV), a major causative agent of hepatocelluar carcinoma (HCC), encodes an oncogenic X-protein (HBx) which has been known as a transcriptional transactivator on multiple viral and celluar promoters. In the report, we verified that HBx transcriptionally repress insulin-like growth factor binding protein-3 (IGFBP-3) by promoting HBx/histone deacetylase 1 (HDAC1) complex formation. HBx recruited HDAC1 forms complex with Sp1 in a p53-independent manner) and deacetylates Sp1 which resulted in the diminished binding of Sp1 on targeted DNA during transcriptional repression. Deacetylation of Sp1 by HBx recruited HDAC1 likely to be a part of the mechanism that controls HBx induced IGFBP-3 repression and the modification of chromatin structure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948152     DOI: 10.1016/j.virusres.2008.09.006

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  17 in total

Review 1.  Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation.

Authors:  Zdenko Herceg; Marie-Pierre Lambert; Karin van Veldhoven; Christiana Demetriou; Paolo Vineis; Martyn T Smith; Kurt Straif; Christopher P Wild
Journal:  Carcinogenesis       Date:  2013-06-07       Impact factor: 4.944

Review 2.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

3.  Host transcription factor Speckled 110 kDa (Sp110), a nuclear body protein, is hijacked by hepatitis B virus protein X for viral persistence.

Authors:  Isha Sengupta; Dipanwita Das; Shivaram Prasad Singh; Runu Chakravarty; Chandrima Das
Journal:  J Biol Chem       Date:  2017-10-18       Impact factor: 5.157

4.  Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?

Authors:  Alla Arzumanyan; Tiffany Friedman; Irene O L Ng; Marcia M Clayton; Zhaorui Lian; Mark A Feitelson
Journal:  Cancer Res       Date:  2011-04-04       Impact factor: 12.701

Review 5.  Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis.

Authors:  Yi Tian; Weibing Yang; Jianxun Song; Yuzhang Wu; Bing Ni
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

6.  Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection.

Authors:  Eiman Aleem; Ayman Elshayeb; Nihal Elhabachi; Amal Refaat Mansour; Ahmed Gowily; Asmaa Hela
Journal:  Oncol Lett       Date:  2011-12-30       Impact factor: 2.967

Review 7.  Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma.

Authors:  Caecilia H C Sukowati; Korri E El-Khobar; Susan I Ie; Beatrice Anfuso; David H Muljono; Claudio Tiribelli
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

8.  HLJ1 is a novel biomarker for colorectal carcinoma progression and overall patient survival.

Authors:  Yong Liu; Jie Zhou; Cuiwei Zhang; Wenguang Fu; Xiuli Xiao; Sibei Ruan; Yuan Zhang; Xia Luo; Mingxi Tang
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

9.  Epigenetic repression of E-cadherin expression by hepatitis B virus x antigen in liver cancer.

Authors:  A Arzumanyan; T Friedman; E Kotei; I O L Ng; Z Lian; M A Feitelson
Journal:  Oncogene       Date:  2011-06-27       Impact factor: 9.867

10.  Epigenetic mechanisms in virus-induced tumorigenesis.

Authors:  Elzbieta Poreba; Justyna Karolina Broniarczyk; Anna Gozdzicka-Jozefiak
Journal:  Clin Epigenetics       Date:  2011-03-23       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.